Unknown

Dataset Information

0

Published Anti-SARS-CoV-2 In Vitro Hits Share Common Mechanisms of Action that Synergize with Antivirals.


ABSTRACT: The global efforts in the past few months have led to the discovery of around 200 drug repurposing candidates for COVID-19. Although most of them only exhibited moderate anti- SARS-CoV-2 activity, gaining more insights into their mechanisms of action could facilitate a better understanding of infection and the development of therapeutics. Leveraging large-scale drug-induced gene expression profiles, we found 36% of the active compounds regulate genes related to cholesterol homeostasis and microtubule cytoskeleton organization. The expression change upon drug treatment was further experimentally confirmed in human lung primary small airway. Following bioinformatics analysis on COVID-19 patient data revealed that these genes are associated with COVID-19 patient severity. The expression level of these genes also has predicted power on anti-SARS-CoV-2 efficacy in vitro, which led to the discovery of monensin as an inhibitor of SARS-CoV-2 replication in Vero-E6 cells. The final survey of recent drug- combination data indicated that drugs co-targeting cholesterol homeostasis and microtubule cytoskeleton organization processes more likely present a synergistic effect with antivirals. Therefore, potential therapeutics should be centered around combinations of targeting these processes and viral proteins.

SUBMITTER: Xing J 

PROVIDER: S-EPMC7941614 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8344595 | biostudies-literature
| S-EPMC2493043 | biostudies-literature
| S-EPMC9260038 | biostudies-literature
| S-EPMC3509055 | biostudies-literature
| S-EPMC4599242 | biostudies-literature
| S-EPMC5207667 | biostudies-literature
| S-EPMC2631022 | biostudies-literature
| S-EPMC10017972 | biostudies-literature
| S-EPMC6763590 | biostudies-literature
| S-EPMC6661245 | biostudies-literature